Pub Date : 2025-10-17DOI: 10.1038/s41581-025-01021-5
Reinhard Laubenbacher, Parta Hatamizadeh
Digital twins are a key computational technology for the implementation of personalized approaches to medical care. They are based on computational models that have been calibrated to an individual patient and can be used to identify personalized treatment approaches. Nephrology offers several promising potential applications for this technology.
{"title":"The promise of digital twins as a tool for personalized approaches in nephrology","authors":"Reinhard Laubenbacher, Parta Hatamizadeh","doi":"10.1038/s41581-025-01021-5","DOIUrl":"10.1038/s41581-025-01021-5","url":null,"abstract":"Digital twins are a key computational technology for the implementation of personalized approaches to medical care. They are based on computational models that have been calibrated to an individual patient and can be used to identify personalized treatment approaches. Nephrology offers several promising potential applications for this technology.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"22 1","pages":"3-4"},"PeriodicalIF":39.8,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145311184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1038/s41581-025-01016-2
Somkanya Tungsanga, Ikechi G. Okpechi, Maria Eugenia V. Bianchi, Swasti Chaturvedi, David Collister, Harley Crowshoe, Giselle M. Rodriguez de Sosa, Habibu A. Galadanci, Erin Hedin, Kwaifa S. Ibrahim, Arsh K. Jain, Irene L. Noronha, Robin L. Erickson, Jaquelyne T. Hughes, Paul Komenda, Win Kulvichit, Roberto Pecoits-Filho, Kalani L. Raphael, Vallabh O. Shah, Malama Tafuna’i, Caroline Tait, Catherine Turner, Curtis Walker, Robert Walker, Cathy Woods, Adeera Levin, Aminu K. Bello
Approximately 480 million individuals worldwide (~6% of the global population) are Indigenous peoples. Despite their diverse cultures and histories, the shared legacy of colonialism has profoundly shaped their health and socioeconomic status. This legacy is deeply intertwined with poverty, systemic racism and historical trauma, contributing to significant health disparities compared with non-Indigenous populations. Among the many chronic diseases disproportionately affecting Indigenous peoples, chronic kidney disease (CKD) stands out as a major public health concern. Indigenous peoples experience higher rates of CKD, yet they often face barriers to accessing responsive and culturally safe health-care services. Factors such as geographic isolation, socioeconomic disadvantages and systemic discrimination limit their access to preventive care, early disease detection and kidney replacement therapy, leading to worse health outcomes and higher mortality rates. Exposure to environmental and occupational risks and inadequate infrastructure further exacerbate CKD risk for Indigenous peoples. Here, we examine determinants of kidney disease and health among major Indigenous populations in Africa, Asia, Australia, Canada, Latin America, Aotearoa–New Zealand, the Pacific Islands and the USA. We discuss culturally safe and responsive strategies that can improve the delivery of kidney care and make policy recommendations for multiple levels of government to ensure health-care systems are equipped to meet the needs of Indigenous communities. By addressing these gaps and promoting cultural competence in kidney care, health-care providers can have a crucial role in reducing health disparities and improving Indigenous peoples’ kidney health worldwide. Indigenous peoples are disproportionally affected by poor kidney health outcomes globally. Here, a group of Indigenous and non-Indigenous authors provide a global overview of kidney health among Indigenous populations across different regions and its key determinants, including structural factors, and make actionable policy recommendations for addressing these health inequities.
{"title":"Global landscape of kidney health across Indigenous populations","authors":"Somkanya Tungsanga, Ikechi G. Okpechi, Maria Eugenia V. Bianchi, Swasti Chaturvedi, David Collister, Harley Crowshoe, Giselle M. Rodriguez de Sosa, Habibu A. Galadanci, Erin Hedin, Kwaifa S. Ibrahim, Arsh K. Jain, Irene L. Noronha, Robin L. Erickson, Jaquelyne T. Hughes, Paul Komenda, Win Kulvichit, Roberto Pecoits-Filho, Kalani L. Raphael, Vallabh O. Shah, Malama Tafuna’i, Caroline Tait, Catherine Turner, Curtis Walker, Robert Walker, Cathy Woods, Adeera Levin, Aminu K. Bello","doi":"10.1038/s41581-025-01016-2","DOIUrl":"10.1038/s41581-025-01016-2","url":null,"abstract":"Approximately 480 million individuals worldwide (~6% of the global population) are Indigenous peoples. Despite their diverse cultures and histories, the shared legacy of colonialism has profoundly shaped their health and socioeconomic status. This legacy is deeply intertwined with poverty, systemic racism and historical trauma, contributing to significant health disparities compared with non-Indigenous populations. Among the many chronic diseases disproportionately affecting Indigenous peoples, chronic kidney disease (CKD) stands out as a major public health concern. Indigenous peoples experience higher rates of CKD, yet they often face barriers to accessing responsive and culturally safe health-care services. Factors such as geographic isolation, socioeconomic disadvantages and systemic discrimination limit their access to preventive care, early disease detection and kidney replacement therapy, leading to worse health outcomes and higher mortality rates. Exposure to environmental and occupational risks and inadequate infrastructure further exacerbate CKD risk for Indigenous peoples. Here, we examine determinants of kidney disease and health among major Indigenous populations in Africa, Asia, Australia, Canada, Latin America, Aotearoa–New Zealand, the Pacific Islands and the USA. We discuss culturally safe and responsive strategies that can improve the delivery of kidney care and make policy recommendations for multiple levels of government to ensure health-care systems are equipped to meet the needs of Indigenous communities. By addressing these gaps and promoting cultural competence in kidney care, health-care providers can have a crucial role in reducing health disparities and improving Indigenous peoples’ kidney health worldwide. Indigenous peoples are disproportionally affected by poor kidney health outcomes globally. Here, a group of Indigenous and non-Indigenous authors provide a global overview of kidney health among Indigenous populations across different regions and its key determinants, including structural factors, and make actionable policy recommendations for addressing these health inequities.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"22 2","pages":"99-121"},"PeriodicalIF":39.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1038/s41581-025-01010-8
The November 2025 issue of Nature Reviews Nephrology marks the 20th anniversary of the journal. It is a time to reflect on advances in the field and the role of the journal in a time of change.
{"title":"20 years of Nature Reviews Nephrology","authors":"","doi":"10.1038/s41581-025-01010-8","DOIUrl":"10.1038/s41581-025-01010-8","url":null,"abstract":"The November 2025 issue of Nature Reviews Nephrology marks the 20th anniversary of the journal. It is a time to reflect on advances in the field and the role of the journal in a time of change.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"21 11","pages":"717-717"},"PeriodicalIF":39.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41581-025-01010-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-15DOI: 10.1038/s41581-025-01015-3
Glenda V. Roberts, Thelma Barber, Nichole M. Jefferson, Quenton Turner-Gee, Denay Richards, Robert Sanchez, David Rush, Ololade A. Williams, Dinushika Mohottige
In early 2025, nearly 2,100 research projects funded by the US National Institutes of Health (NIH) were terminated. Numerous calls for depoliticization of the NIH’s scientific mission culminated in the Bethesda declaration, which has now been signed by over 32,000 individuals. However, little attention has been given to the effect of these terminations on people who stand to benefit most from scientific discoveries: the patients, care partners and community leaders.
{"title":"Harms of terminating NIH grants for kidney disease","authors":"Glenda V. Roberts, Thelma Barber, Nichole M. Jefferson, Quenton Turner-Gee, Denay Richards, Robert Sanchez, David Rush, Ololade A. Williams, Dinushika Mohottige","doi":"10.1038/s41581-025-01015-3","DOIUrl":"10.1038/s41581-025-01015-3","url":null,"abstract":"In early 2025, nearly 2,100 research projects funded by the US National Institutes of Health (NIH) were terminated. Numerous calls for depoliticization of the NIH’s scientific mission culminated in the Bethesda declaration, which has now been signed by over 32,000 individuals. However, little attention has been given to the effect of these terminations on people who stand to benefit most from scientific discoveries: the patients, care partners and community leaders.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"21 12","pages":"815-816"},"PeriodicalIF":39.8,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145296206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-09DOI: 10.1038/s41581-025-01011-7
Jurriën Prins, Annabelle Biscans, Anton Jan van Zonneveld, Kendall S. Frazier, Eric P. van der Veer
In the past decade, RNA-based therapeutic strategies have transitioned from drugs of promise to transformative treatments for a range of previously untreatable diseases. This transition has largely been driven by a growing comprehension of individual cell types and corresponding transcriptomes in healthy and diseased tissues. However, despite their natural and abundant distribution to the kidney, successful RNA-based therapeutics for kidney diseases are scarce, as the overwhelming majority of administered drugs are either rapidly excreted, localize to non-targeted cells or are unproductive owing to endolysosomal compartmentalization. The limited success in developing RNA-based therapies for this vital organ have led to considerable doubt regarding the targetability and suitability of splice modulation, small interfering or activating RNAs, microRNA mimics or antagonists, aptamers or editing strategies for the treatment of kidney diseases. Strategies to target specific cell types within the kidney and improve the productive uptake of RNA-based drugs are needed to improve the therapeutic efficacy and safety of RNA-based therapies. Despite these challenges, a number of RNA-based therapeutic approaches are being explored for a variety of kidney diseases and hold promise for future validation. Progress in the development of RNA-based therapeutics has been accelerated by the identification of organ-enriching carriers and cell-specific targeting conjugates, leading to their approval for a range of indications. However, attempts to develop RNA-based therapeutics for kidney diseases have proved challenging. This Review describes the physiological, technological and pharmacological hurdles that need to be overcome to realize the potential of RNA therapeutic approaches to kidney diseases.
{"title":"RNA-based therapeutic opportunities for the treatment of kidney diseases","authors":"Jurriën Prins, Annabelle Biscans, Anton Jan van Zonneveld, Kendall S. Frazier, Eric P. van der Veer","doi":"10.1038/s41581-025-01011-7","DOIUrl":"10.1038/s41581-025-01011-7","url":null,"abstract":"In the past decade, RNA-based therapeutic strategies have transitioned from drugs of promise to transformative treatments for a range of previously untreatable diseases. This transition has largely been driven by a growing comprehension of individual cell types and corresponding transcriptomes in healthy and diseased tissues. However, despite their natural and abundant distribution to the kidney, successful RNA-based therapeutics for kidney diseases are scarce, as the overwhelming majority of administered drugs are either rapidly excreted, localize to non-targeted cells or are unproductive owing to endolysosomal compartmentalization. The limited success in developing RNA-based therapies for this vital organ have led to considerable doubt regarding the targetability and suitability of splice modulation, small interfering or activating RNAs, microRNA mimics or antagonists, aptamers or editing strategies for the treatment of kidney diseases. Strategies to target specific cell types within the kidney and improve the productive uptake of RNA-based drugs are needed to improve the therapeutic efficacy and safety of RNA-based therapies. Despite these challenges, a number of RNA-based therapeutic approaches are being explored for a variety of kidney diseases and hold promise for future validation. Progress in the development of RNA-based therapeutics has been accelerated by the identification of organ-enriching carriers and cell-specific targeting conjugates, leading to their approval for a range of indications. However, attempts to develop RNA-based therapeutics for kidney diseases have proved challenging. This Review describes the physiological, technological and pharmacological hurdles that need to be overcome to realize the potential of RNA therapeutic approaches to kidney diseases.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"22 1","pages":"12-29"},"PeriodicalIF":39.8,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-09DOI: 10.1038/s41581-025-01007-3
Kumar Sharma, Jens Hansen, Katalin Susztak, Livia Eberlin, Christopher R. Anderton, Theodore Alexandrov, Ravi Iyengar
Precision medicine is now a feasible prospect for nephrologists as numerous therapeutic options are available for various forms of kidney disease. However, implementation of this strategy will require high-dimensional diagnostic approaches to identify patients who will respond to an intervention and monitor mechanisms of action relevant to the underlying disease process. With the advent of spatial omics, comprehensive and thorough molecular analysis of biological samples is now possible. In particular, spatial metabolomics analysis of kidney biopsy samples could have an important role in facilitating precision medicine for kidney diseases. Spatial metabolomics can be used to monitor changes in the functional outcomes of genes and proteins in specific anatomical compartments such as the glomeruli, tubules, blood vessels and interstitial spaces. Spatial metabolomics studies have identified adenine in regions of interstitial fibrosis and arteriosclerosis in diabetic kidney disease, provided new insights into the regulation of N-glycans in glomeruli from patients with diabetes, and enabled a new metabolomic classification of kidney cancer subtypes. Use of computational informatic platforms to integrate genomics, transcriptomics, proteomics and epigenomics with metabolomics will further enhance the value of spatial metabolomics for clinical applications. Here, the authors discuss how spatial metabolomics could contribute to better understanding of cellular mechanisms in kidney health and disease, as well as the discovery of blood and urine biomarkers and drug targets for new therapies to halt kidney disease progression.
{"title":"Spatial metabolomics and multiomics integration for breakthroughs in precision medicine for kidney disease","authors":"Kumar Sharma, Jens Hansen, Katalin Susztak, Livia Eberlin, Christopher R. Anderton, Theodore Alexandrov, Ravi Iyengar","doi":"10.1038/s41581-025-01007-3","DOIUrl":"10.1038/s41581-025-01007-3","url":null,"abstract":"Precision medicine is now a feasible prospect for nephrologists as numerous therapeutic options are available for various forms of kidney disease. However, implementation of this strategy will require high-dimensional diagnostic approaches to identify patients who will respond to an intervention and monitor mechanisms of action relevant to the underlying disease process. With the advent of spatial omics, comprehensive and thorough molecular analysis of biological samples is now possible. In particular, spatial metabolomics analysis of kidney biopsy samples could have an important role in facilitating precision medicine for kidney diseases. Spatial metabolomics can be used to monitor changes in the functional outcomes of genes and proteins in specific anatomical compartments such as the glomeruli, tubules, blood vessels and interstitial spaces. Spatial metabolomics studies have identified adenine in regions of interstitial fibrosis and arteriosclerosis in diabetic kidney disease, provided new insights into the regulation of N-glycans in glomeruli from patients with diabetes, and enabled a new metabolomic classification of kidney cancer subtypes. Use of computational informatic platforms to integrate genomics, transcriptomics, proteomics and epigenomics with metabolomics will further enhance the value of spatial metabolomics for clinical applications. Here, the authors discuss how spatial metabolomics could contribute to better understanding of cellular mechanisms in kidney health and disease, as well as the discovery of blood and urine biomarkers and drug targets for new therapies to halt kidney disease progression.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"22 2","pages":"152-164"},"PeriodicalIF":39.8,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-08DOI: 10.1038/s41581-025-01019-z
Dibya Singh Shah (, )
The success of the kidney transplantation programme in Nepal offers lessons in persistence, collaboration and policy reform. In low-resource settings, access to transplantation remains limited, but locally led efforts — supported by training and political will — can shift the landscape and make equitable transplant care possible.
{"title":"Insights from Nepal into implementing transplantation programmes in low-resource settings","authors":"Dibya Singh Shah \u0000 (, )","doi":"10.1038/s41581-025-01019-z","DOIUrl":"10.1038/s41581-025-01019-z","url":null,"abstract":"The success of the kidney transplantation programme in Nepal offers lessons in persistence, collaboration and policy reform. In low-resource settings, access to transplantation remains limited, but locally led efforts — supported by training and political will — can shift the landscape and make equitable transplant care possible.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"21 12","pages":"812-812"},"PeriodicalIF":39.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-07DOI: 10.1038/s41581-025-01008-2
Antonia Vlahou, Raymond Vanholder
Albuminuria and estimates of glomerular filtration rate remain the main diagnostic and monitoring metrics used in people with chronic kidney disease (CKD). Although these are both useful markers of kidney disease, they represent the consequence rather than the cause of CKD, can neither detect disease at its earliest stages nor determine its aetiology, and are often suboptimal in guiding therapeutic intervention. By contrast, nucleotide, protein, peptide and metabolite findings from urine can provide a wealth of information about kidney-tissue biology and pathological processes, thereby representing a source of potential biomarkers for early disease detection, prognostication and therapeutic guidance. Urinary biomarker research is currently dominated by studies of protein biomarkers that reflect tissue injury and repair, inflammation and fibrosis, and can be combined for use in multi-marker panels. Data on biomarkers for guiding therapy are scarce, underscoring the urgent need for more targeted studies, given the availability of several new therapies that are effective in attenuating CKD progression and improving patient outcomes. Consequently, although several (mainly protein) biomarkers with evidenced potential to improve disease management are currently available, their clinical implementation is limited by the paucity of clinical and health-economic impact data, especially data on the combined use of urinary biomarkers and the latest therapies available for people with CKD. Urinary components can reflect kidney biology in health and disease. Here, the authors examine current data on urinary biomarkers that can provide insight into kidney function and metabolism, and discuss their potential application value as diagnostic, prognostic and/or therapeutic monitoring biomarkers.
{"title":"Urine as a source of biomarkers and biological knowledge in chronic kidney disease","authors":"Antonia Vlahou, Raymond Vanholder","doi":"10.1038/s41581-025-01008-2","DOIUrl":"10.1038/s41581-025-01008-2","url":null,"abstract":"Albuminuria and estimates of glomerular filtration rate remain the main diagnostic and monitoring metrics used in people with chronic kidney disease (CKD). Although these are both useful markers of kidney disease, they represent the consequence rather than the cause of CKD, can neither detect disease at its earliest stages nor determine its aetiology, and are often suboptimal in guiding therapeutic intervention. By contrast, nucleotide, protein, peptide and metabolite findings from urine can provide a wealth of information about kidney-tissue biology and pathological processes, thereby representing a source of potential biomarkers for early disease detection, prognostication and therapeutic guidance. Urinary biomarker research is currently dominated by studies of protein biomarkers that reflect tissue injury and repair, inflammation and fibrosis, and can be combined for use in multi-marker panels. Data on biomarkers for guiding therapy are scarce, underscoring the urgent need for more targeted studies, given the availability of several new therapies that are effective in attenuating CKD progression and improving patient outcomes. Consequently, although several (mainly protein) biomarkers with evidenced potential to improve disease management are currently available, their clinical implementation is limited by the paucity of clinical and health-economic impact data, especially data on the combined use of urinary biomarkers and the latest therapies available for people with CKD. Urinary components can reflect kidney biology in health and disease. Here, the authors examine current data on urinary biomarkers that can provide insight into kidney function and metabolism, and discuss their potential application value as diagnostic, prognostic and/or therapeutic monitoring biomarkers.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"22 1","pages":"69-84"},"PeriodicalIF":39.8,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-29DOI: 10.1038/s41581-025-01013-5
Ellen F. Carney
{"title":"Inhibitory effects of oestradiol on ferroptosis may underlie sex differences in AKI","authors":"Ellen F. Carney","doi":"10.1038/s41581-025-01013-5","DOIUrl":"10.1038/s41581-025-01013-5","url":null,"abstract":"","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"21 11","pages":"725-725"},"PeriodicalIF":39.8,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-29DOI: 10.1038/s41581-025-01014-4
Katherine A. Barraclough, Karin G. F. Gerritsen
{"title":"Author Correction: Green nephrology: from evidence to action","authors":"Katherine A. Barraclough, Karin G. F. Gerritsen","doi":"10.1038/s41581-025-01014-4","DOIUrl":"10.1038/s41581-025-01014-4","url":null,"abstract":"","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"21 11","pages":"809-809"},"PeriodicalIF":39.8,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41581-025-01014-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：